IP Library Granted Patent US 7,381,399
Granted Patent B2
US 7,381,399 · App. 10/386,403 · Granted Jun 3, 2008

Technetium-dipyridine complexes, and methods of use thereof

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,381,399
App. No.
10/386,403
Granted
Jun 3, 2008
Kind
B2
Abstract

One aspect of the invention relates to novel complexes of technetium (Tc) with various heteroaromatic ligands, e.g., pyridyl and imidazolyl ligands, and their use in radiopharmaceuticals for a variety of clinical diagnostic and therapeutic applications. Another aspect of the invention relates to novel pyridyl ligands that form a portion of the aforementioned complexes. Methods for the preparation of the technetium complexes are also described. Another aspect of the invention relates to novel pyridyl ligands based on derivatized lysine, alanine and bis-amino acids for conjugation to small peptides by solid phase synthetic methods. Additionally, the invention relates to methods for imaging regions of a mammal using the complexes of the invention.

Claims (33)

1. A complex comprising a radionuclide complexed with a compound represented by A:

wherein:

R is selected from the group consisting of H, alkyl, hydroxyalkyl, alkoxyalkyl, aminoalkyl, thioalkyl, alkenyl, alkynyl, aryl, heteroaryl, aralkyl, heteroaralkyl, acyl, aminoacyl, hydroxyacyl, thioacyl, —CO 2 H, —(CH 2 ) d —R 80 , and an amino acid radical;

R′ is absent or present from 1 to 4 times;

R″ is absent or present from 1 to 4 times;

each instance of R′ or R″ is selected independently from the group consisting of halogen, alkyl, alkenyl, alkynyl, hydroxyl, alkoxyl, acyl, acyloxy, acylamino, silyloxy, amino, nitro, sulfhydryl, alkylthio, imino, amido, phosphoryl, phosphonate, phosphine, carbonyl, carboxyl, carboxamide, anhydride, silyl, thioalkyl, alkylsulfonyl, arylsulfonyl, selenoalkyl, ketone, aldehyde, ester, heteroalkyl, cyano, guanidine, amidine, acetal, ketal, amine oxide, aryl, heteroaryl, aralkyl, heteroaralkyl, azido, aziridine, carbamoyl, epoxide, hydroxamic acid, imide, oxime, sulfonamide, thioamide, thiocarbamate, urea, thiourea, and —(CH 2 ) d —R 80 ;

R 80 represents independently for each occurrence carboxaldehyde, carboxylate, carboxamido, alkoxycarbonyl, aryloxycarbonyl, ammonium, aryl, heteroaryl, cycloalkyl, cycloalkenyl, heterocyclyl, polycyclyl, amino acid, peptide, saccharide, ribonucleic acid, or (deoxy)ribonucleic acid;

d is an integer in the range 0 to 12 inclusive;

m is an integer in the range 0 to 6 inclusive; and

n is an integer in the range 0 to 6 inclusive.

2. The complex of claim 1 , wherein said radionuclide is technetium or rhenium.

3. The complex of claim 1 , wherein m is 1.

4. The complex of claim 1 , wherein n is 1.

5. The complex of claim 1 , wherein m is 1; and n is 1.

6. The complex of claim 1 , wherein R′ is absent.

7. The complex of claim 1 , wherein R″ is absent.

8. The complex of claim 1 , wherein R′ is absent; and R″ is absent.

9. The complex of claim 1 , wherein m is 1; n is 1; R′ is absent; and R″ is absent.

10. The complex of claim 1 , wherein R is —(CH 2 ) d —R 80 .

11. The complex of claim 1 , wherein m is 1; n is 1; R′ is absent; R″ is absent; and R is —(CH 2 ) d —R 80 .

12. The complex of claim 1 , wherein m is 1; n is 1; R′ is absent; R″ is absent; and R is —(CH 2 ) d —R 80 ; wherein said radionuclide is technetium or rhenium.

13. The complex of claim 1 , wherein R is an amino acid radical.

14. The complex of claim 1 , wherein R is an amino acid radical; m is 1; and n is 1.

15. The complex of claim 1 , wherein R is an amino acid radical; m is 1; n is 1; R′ is absent; and R″ is absent.

16. The complex of claim 1 , wherein R is an amino acid radical; m is 1; n is 1; R′ is absent; and R″ is absent; wherein said radionuclide is technetium or rhenium.

17. The complex of claim 1 , wherein the amino acid radical is —CH 2 CH 2 CH 2 CH 2 CH(NH 2 )CO 2 H.

18. The complex of claim 1 , wherein the amino acid radical is —CH(CO 2 H)CH 2 CH 2 CH 2 CH 2 NH 2 .

19. The complex of claim 1 , wherein the amino acid radical is —CH 2 CH 2 CO 2 H.

20. The complex of claim 1 , wherein the amino acid radical is —CH(CO 2 H)(CH 2 ) x CH(NH 2 )CO 2 H, wherein x is an integer from 3 to 9 inclusively.

21. A formulation, comprising a complex according to any of claims 1 , 2 - 11 , 12 - 15 , or 16 - 20 ; and a pharmaceutically acceptable excipient.

22. A method of imaging a region in a patient, comprising the steps of: administering to a patient a diagnostically effective amount of a complex of claim 1 ; and obtaining an image of said region of said patient.

23. The method of claim 22 , wherein said region of said patient is the head or thorax.

24. A method of preparing a peptide conjugate incorporating a complex of claim 13 wherein the peptide conjugate is prepared using solid phase synthetic techniques.

Assignments (4)
RELEASE OF SECURITY INTEREST Recorded Dec 2, 2022
From: WELLS FARGO BANK, N.A.
To: PROGENICS PHARMACEUTICALS, INC.; MOLECULAR INSIGHT PHARMACEUTICALS, INC.; PSMA DEVELOPMENT COMPANY, LLC
Reel/Frame 062047/0915 →
SECURITY INTEREST Recorded Dec 2, 2022
From: LANTHEUS MEDICAL IMAGING, INC.; MOLECULAR INSIGHT PHARMACEUTICALS, INC.; PSMA DEVELOPMENT COMPANY, LLC; PROGENICS PHARMACEUTICALS, INC.
To: CITIZENS BANK, N.A.
Reel/Frame 062047/0960 →
SECURITY AGREEMENT Recorded Aug 19, 2020
From: PROGENICS PHARMACEUTICALS, INC.; MOLECULAR INSIGHT PHARMACEUTICALS, INC.; PSMA DEVELOPMENT COMPANY LLC
To: WELLS FARGO BANK, N.A.
Reel/Frame 053538/0666 →
RELEASE OF PATENT SECURITY INTEREST Recorded Jan 18, 2013
From: NEXBANK, SSB (AS COLLATERAL AGENT)
To: MOLECULAR INSIGHT PHARMACEUTICALS, INC.
Reel/Frame 029660/0618 →